Publications by authors named "A Zer"

Claim this Profile
E
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
A Zer, M-J Ahn, F Barlesi, L Bubendorf, D De Ruysscher

Ann Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I Spira, Alona Zer

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing First-Line Treatment in BRAF V600-Mut NSCLC-The Jury Is Still Out.
Alona Zer, Jair Bar

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.
Francois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, Alona Zer, Laurent Greillier

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
Byoung Chul Cho, Melissa Johnson, Jair Bar, Eric Schaefer, Kiyotaka Yoh, Alona Zer

Lung Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis